Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,438 | -1,663 | -828 | -3,555 | -2,822 |
| Depreciation Amortization | 7 | 5 | 2 | 11 | 9 |
| Accounts payable and accrued liabilities | -309 | -105 | -186 | 807 | 654 |
| Other Working Capital | 384 | 394 | 190 | 446 | 482 |
| Other Operating Activity | 345 | 127 | 198 | -751 | -609 |
| Operating Cash Flow | $-2,011 | $-1,242 | $-624 | $-3,042 | $-2,287 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,225 | 1,325 | 600 | 1,628 | 1,060 |
| Other Financing Activity | -235 | -153 | -84 | -260 | -166 |
| Financing Cash Flow | $1,990 | $1,172 | $516 | $1,368 | $894 |
| Exchange Rate Effect | -1 | -3 | -2 | -2 | -3 |
| Beginning Cash Position | 1,432 | 1,432 | 1,432 | 3,107 | 3,107 |
| End Cash Position | 1,410 | 1,359 | 1,322 | 1,432 | 1,711 |
| Net Cash Flow | $-22 | $-73 | $-110 | $-1,675 | $-1,396 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,011 | -1,242 | -624 | -3,042 | -2,287 |
| Free Cash Flow | -2,011 | -1,242 | -624 | -3,042 | -2,287 |